Last reviewed · How we verify
NCT05937958: MARGARITA
MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible (MARGARITA)
trial in Cervical Cancer in 30 participants. Currently enrolling.
1 October 2025
Quick facts
| Lead sponsor | UMC Utrecht |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 April 2023 |
| Primary completion | 1 October 2025 |
| Estimated completion | 1 October 2027 |
| Sites | 2 locations across Denmark, Netherlands |
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
Sponsor
UMC Utrecht — full company profile →
Who can join
18 and older, female only, with Cervical Cancer or Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to explore the effectiveness and side effects of a high dose daily adapted SBRT (stereotactic body radiotherapy) boost delivered with MRLinac in patients with gynaecological cancers that cannot receive a brachytherapy boost to the primary tumour for different reasons (medical conditions, tumour extensions, etc). Current alternative for brachytherapy in these situations is often a non-adaptive conebeam- CT guided boost. Conebeam-CT guided non-adaptive high dose SBRT in under these circumstances is described being quite toxic. The main questions this study aims to answer are: * In how many cases could local control (i.e. total disappearance of the tumor) is be achieved with this treatment? * Which side effects are observed in patients receiving this treatment? Participants will be asked to fill out questionnaires (e.g. regarding side effects). Furthermore, participants are asked if their clinical data may be used for study purposes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Dosimetric comparison between brachytherapy and MR-Linac as a boost modality for locally advanced cervical cancer.
van Noortwijk R, Kroon PS, van Vliet-van den Ende KM, Brondijk EH, et al · · 2026 · PMID 41537166 · DOI 10.1016/j.ctro.2025.101098
Verify or expand the search:
- PubMed search for NCT05937958
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Other UMC Utrecht trials
Trials by the same sponsor.
- NCT07512336 — A Randomized Intra-Patient Controlled Trial of MagnetOs™ Putty vs Autograft in Instrumented Posterolateral Spinal Fusion · NA · not yet recruiting
- NCT07485985 — Coronary Sinus Reducer Therapy for Persisting Angina · NA · not yet recruiting
- NCT07449052 — Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease · NA · not yet recruiting
- NCT05375708 — Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Me · Phase 2 · suspended
- NCT06898541 — Coronary Sinus Reducer in Coronary Microvascular Disease · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05937958 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UMC Utrecht
- Last refreshed: 18 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05937958.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing